New combo therapy shows promise for tough bile duct cancer

NCT ID NCT07159204

Ongoing Disease control Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This Phase 2 trial is testing a combination of paclitaxel polymer micelle and immunotherapy for people with advanced biliary tract cancer whose disease has progressed after standard first-line treatment. The study aims to see if this new drug combo can shrink tumors and control the cancer. About 100 participants will be enrolled at Peking Union Medical College Hospital.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: paclitaxel polymer micelle combined with immunotherapy
What this could lead to: If successful, this could offer a new treatment option for advanced biliary tract cancer patients who have exhausted standard first-line therapy.
What could go wrong: This is an early Phase 2 trial with only 100 participants, so results may not be conclusive. The combination therapy may cause significant side effects and may not improve outcomes for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER (BTC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BILIARY TRACT CANCER (BTC)

Contacts and locations

Locations

Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.